Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 5/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21450326 | 0.93 | NT5E (0.44) | NT5ECCNE2CCNE1CDK2ADORA3 | |
| SCHEMBL21450327 | 0.91 | NT5E (0.42) | NT5ECCNE2CCNE1CDK2CDK1 | |
| SCHEMBL19370264 | 0.88 | NT5E (0.42) | NT5EADORA3TP53 | |
| SCHEMBL19370346 | 0.85 | NT5E (0.41) | NT5ECCNE2CCNE1CDK2CDK1 | |
| SCHEMBL19370330 | 0.79 | NT5E (0.42) | NT5ECDK1 | |
| SCHEMBL19349798 | 0.77 | NT5E (0.69) | NT5EADORA3 | |
| SCHEMBL24078851 | 0.76 | NT5E (0.49) | NT5EADORA3 | |
| SCHEMBL21450282 | 0.73 | NT5E (0.41) | NT5ECDK1 | |
| SCHEMBL19100848 | 0.73 | NT5E (0.71) | NT5EADORA3 | |
| SCHEMBL22843467 | 0.72 | NT5E (0.55) | NT5ECCNE2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001603-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-20210002322-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001603-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | NT5E 3/4885CCNE2 4852/4885CCNE1 4743/4885 |
| US-20210002322-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | NT5E 3/4885CCNE2 4854/4885CCNE1 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.